Artesunate, Imatinib, and Infliximab in COVID-19: A Rapid Review and Meta-analysis of Current Evidence

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2022 May 31

PMID 35634954

Authors

Bahman Amani

Sara Zareei

Behnam Amani

Mahsa Zareei

Neda Zareei

Rouhollah Shabestan

Arash Akbarzadeh

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Despite the pervasive vaccination program against coronavirus disease 2019 (COVID-19), fully vaccinated people are still being infected by severe acute respiratory syndrome coronavirus 2, making an effective and safe therapeutic intervention a crucial need for the patients' survival. The purpose of the present study is to seek available evidence for the efficacy and safety of three promising medications artesunate, imatinib, and infliximab against COVID-19.

Methods: A literature search was conducted in PubMed, Cochrane Library, medRxive, and Google Scholar up to January 2022. Furthermore, the clinical trial databases were screened to find more citations. The Cochrane Collaboration tool and Newcastle-Ottawa scale were used to assess the included studies. Meta-analysis was performed using RevMan 5.4.1.

Results: Five published studies were identified as eligible. Meta-analysis showed that there was no significant difference between the infliximab and control groups in terms of mortality rate (risk ratio [RR]: 0.65; 95% confidence interval [CI]: 0.40-1.07; p = 0.09). However, a significant difference was observed between the two groups for the hospital discharge (RR: 1.37; 95% CI: 1.04-1.80; p = 0.03). No remarkable clinical benefit was observed in favor of using imatinib for COVID-19 patients. Artesunate showed significant improvement in patients with COVID-19.

Conclusion: In the present, limited evidence exists for the efficacy and safety of artesunate, imatinib, and infliximab in patients with COVID-19. The findings of WHO's Solidarity international trial will provide further information regarding these therapeutic interventions.

Citing Articles

The Impact of Infliximab on Hyperinflammation State in Hospitalized COVID-19 Patients: A Retrospective Study.

Saied Y, Abou Warda A, Allam R, Syed W, Al-Rawi M, Iqbal A Medicina (Kaunas). 2024; 60(10).

PMID: 39459457 PMC: 11509666. DOI: 10.3390/medicina60101670.

Remdesivir in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis.

Navidi Z, Pakzad Moghadam S, Iravani M, Orandi A, Orandi A, Ghazi S Clin Transplant Res. 2024; 38(3):212-221.

PMID: 39344698 PMC: 11464156. DOI: 10.4285/ctr.24.0031.

Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis.

Khorramnia S, Navidi Z, Orandi A, Iravani M, Orandi A, Malekabad E Clin Transplant Res. 2024; 38(2):136-144.

PMID: 38904088 PMC: 11228381. DOI: 10.4285/ctr.24.0015.

References

Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T . Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study. Ophthalmology. 2014; 121(10):1877-84. DOI: 10.1016/j.ophtha.2014.04.042. View

Fisher B, Veenith T, Slade D, Gaskell C, Rowland M, Whitehouse T . Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir Med. 2021; 10(3):255-266. PMC: 8676420. DOI: 10.1016/S2213-2600(21)00460-4. View

Kujak C, Kolesar J . Treatment of chronic myelogenous leukemia. Am J Health Syst Pharm. 2016; 73(3):113-20. DOI: 10.2146/ajhp140686. View

Storkanova H, Oreska S, Spiritovic M, Hermankova B, Bubova K, Komarc M . Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Sci Rep. 2021; 11(1):1. PMC: 7791137. DOI: 10.1038/s41598-020-79139-8. View

Amani B, Amani B, Zareei S, Zareei M . Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis. Immun Inflamm Dis. 2021; 9(4):1197-1208. PMC: 8426686. DOI: 10.1002/iid3.502. View

Krishna S, Ganapathi S, Chis Ster I, Saeed M, Cowan M, Finlayson C . A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. EBioMedicine. 2015; 2(1):82-90. PMC: 4484515. DOI: 10.1016/j.ebiom.2014.11.010. View

Chauhan A, Min K, Kwon T . RIP1-dependent reactive oxygen species production executes artesunate-induced cell death in renal carcinoma Caki cells. Mol Cell Biochem. 2017; 435(1-2):15-24. DOI: 10.1007/s11010-017-3052-7. View

Cheng C, Ng D, Chan T, Guan S, Ho W, Koh A . Anti-allergic action of anti-malarial drug artesunate in experimental mast cell-mediated anaphylactic models. Allergy. 2012; 68(2):195-203. DOI: 10.1111/all.12077. View

OBrien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11):994-1004. DOI: 10.1056/NEJMoa022457. View

10.

Gleich G, Leiferman K, Pardanani A, Tefferi A, Butterfield J . Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002; 359(9317):1577-8. DOI: 10.1016/S0140-6736(02)08505-7. View

11.

Droogendijk H, Kluin-Nelemans H, van Doormaal J, Oranje A, van de Loosdrecht A, van Daele P . Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006; 107(2):345-51. DOI: 10.1002/cncr.21996. View

12.

Efferth T, Romero M, Wolf D, Stamminger T, Marin J, Marschall M . The antiviral activities of artemisinin and artesunate. Clin Infect Dis. 2008; 47(6):804-11. DOI: 10.1086/591195. View

13.

Dyall J, Coleman C, Hart B, Venkataraman T, Holbrook M, Kindrachuk J . Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014; 58(8):4885-93. PMC: 4136000. DOI: 10.1128/AAC.03036-14. View

14.

Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z . Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020; 93(1):481-490. PMC: 7361300. DOI: 10.1002/jmv.26256. View

15.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

16.

Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G . Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2004; 64(2):229-34. PMC: 1755337. DOI: 10.1136/ard.2004.025130. View

17.

Lee K, Jeen Y, Cho J, Lee C, Koo J, Park D . Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol. 2013; 28(12):1829-33. DOI: 10.1111/jgh.12324. View

18.

Gignoux E, Azman A, De Smet M, Azuma P, Massaquoi M, Job D . Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. N Engl J Med. 2016; 374(1):23-32. DOI: 10.1056/NEJMoa1504605. View

19.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

20.

Lamireau T, Cezard J, Dabadie A, Goulet O, Lachaux A, Turck D . Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2005; 10(6):745-50. DOI: 10.1097/00054725-200411000-00008. View